Scott Brun
President at Gold Mast Consulting
Scott Brun
President at Gold Mast Consulting
Greater Chicago Area
Overview
Work Experience
President
2019 - Current
Gold Mast Consulting, LLC provides technical advice and strategic guidance related to biopharmaceutical research and development, pipeline portfolio management, commercialization of new therapeutics, and strategic communications related to R&D activities. Examples of client collaborations include scientific due diligence for top tier VC firms, assessment and advice on R&D programs for therapeutic start-up companies, and participation on academic and corporate scientific advisory boards.
VP, Corporate Strategy Office, Scientific Affairs and Head, AbbVie Ventures
2016 - 2019
• Responsible for AbbVie's corporate venture investment fund • Leads team of geographically located professionals responsible for identifying and advancing venture investment opportunities within current R&D therapeutic areas as well as new fields and technology platforms of interest • Works with Chief Strategy Officer, Chief Scientific Officer, Chief Financial Officer, and Chief Executive Officer to define and implement fund strategies
Vice President, Pharmaceutical Development
2012 - 2016
• Management responsibility for over 2000 individuals located in 50+ countries and external research budget over $1 billion. • Functions include Global Clinical Operations, Clinical Pharmacology and Pharmacometrics, Data and Statistical Sciences, International Pharmaceutical Development including Japan Development group, Project Management, Development Therapeutic Areas including Project Leadership and Medical/Scientific Clinical Research organizations. • Responsible for leading AbbVie’s advancement of early and late stage clinical development programs across a broad range of therapeutic areas (neuroscience, immunology, oncology, infectious disease, general medicine) including 10 late stage/phase 3 programs and over 20 early and mid-stage development projects • During search for Chief Scientific Officer (May 2013-June 2014), assumed additional responsibilities as interim direct report to CEO -Acted as primary decision maker for clinical stage internal and external programs, including prioritization of ~$1 billion external clinical development budget -Served as primary spokesperson for AbbVie R&D to global media and investors, including R&D representative on multiple quarterly earnings calls. o Collaborated with therapeutic areas VPs and development teams to achieve global regulatory approvals of multiple therapeutics and indications -HCV interferon free combination regimen (Viekira PAK and Viekirax/Exviera) including an unprecedented three new molecular entities achieved several months ahead of schedule -Humira new indication in hidradenitis suppurativa, first therapeutic approved for this condition -Duopa drug/device combination for advanced Parkinson Disease in the US o Steady advancement of a range of mid and late stage pipeline programs
Divisional Vice President, Infectious Disease Development
2009 - 2012
• Responsible for oversight of Abbott’s infectious disease pharmaceutical portfolio through direct management of Anti-infective and Antiviral Global Project Teams • Key accomplishments include leadership of innovative strategy to develop three novel HCV antivirals as an interferon free, all oral combination treatment regimen (Viekira PAK) in highly competitive environment. •Participated in selection of ABT-493/ABT-530 as clinical candidates for next generation pangenotypic all oral HCV regimen
Divisional Vice President, Infectious Disease and Immunology Development
2008 - 2009
• Responsible for oversight of Abbott’s infectious disease and immunology pharmaceutical portfolios through direct management of five Global Project Teams, multidisciplinary organizations responsible for creation and execution of product development strategy across the entire lifecycle (phase I-IV). • Portfolio products include HIV protease inhibitors Kaletra (lopinavir/ritionavir) and Norvir (ritonavir), and RSV prophylactic antibody Synagis (palivizumab). • Development projects include hepatitis C multiple small molecules and biologic treatments in early development for treatment of asthma, multiple sclerosis, and rheumatoid arthritis, including novel dual variable domain bispecific immunoglobulins.
Divisional Vice President, Infectious Disease and Renal Development
2006 - 2008
Responsible for oversight of Abbott’s infectious disease and renal pharmaceutical portfolios through direct management of Anti-infective, Antiviral, and Renal Global Project Teams, multidisciplinary organizations responsible for creation and execution of product development strategy across the entire lifecycle (phase I-IV). • Portfolio products include HIV protease inhibitors, antibiotics Biaxin (clarithromycin) and Omnicef (cefdinir), RSV prophylactic antibodies, and Vitamin D analog Zemplar (paricalcitol). Accomplishments include: • Management oversight of global Kaletra pediatric tablet filing and approval • Leadership of EU mutual recognition process approval of Zemplar capsule therapy for predialysis and dialysis patients • In collaboration with external thought leaders, developed strategy for innovative clinical study program exploring Zemplar cardiorenal protection profile • Successfully obtained R&D senior management approval for early clinical development of novel HCV protease and polymerase inhibitor candidates • Responsibilities also included medical affairs support for Synthroid (thyroid replacement) and erythromycin.
Divisional Vice President , Infectious Disease Development
2004 - 2006
• Responsible for oversight of Abbott’s infectious disease pharmaceutical portfolio through direct management of Anti-infective and Antiviral Global Project Teams • Strategic management of multiple regulatory submissions, including successful filings for once daily Kaletra dosing (US) and improved Kaletra tablet formulation (global) as well as pediatric exclusivity package for Norvir (ritonavir). • Experience developing late stage lifecycle management programs for outpatient respiratory antibiotics Biaxin (clarithromycin) and Omnicef (cefdinir), including patent legal strategy and publication support. • Actively participated in successful negotiations for a co-development opportunity for preclinical hepatitis C protease inhibitors with Enanta Pharmaceuticals, Watertown MA
Global Project Head, Global Medical Director, Antiviral Global Project Team
2002 - 2004
Responsible for directing and coordinating the development and registration of new drug products and management of the life cycle of marketed products within Abbott’s Antiviral Franchise, including Kaletra (lopinavir/ritonavir). • Design and execution of key development projects including new formulation of lopinavir/ritonavir with markedly improved product profile and ground-breaking simplification clinical trials evaluating Kaletra as a single agent for treatment of HIV infection • In collaboration with commercial counterpart, created new Regional Medical Director organization to optimize support of Antiviral Global Medical Affairs projects • Participant/presenter at multiple face-to face meetings with regulatory authorities, specifically the FDA and EMEA, as well as with national HIV treatment guideline committees. • Oral presentations at multiple Abbott sponsored symposia and advisory boards involving top opinion leaders in HIV therapeutics as well as media communications (print and radio) • Broad involvement in Global Pharmaceutical Research and Development initiatives –selected as sole development representative for management committee overseeing creation of new Global Regulatory Affairs division at Abbott as well as steering committee defining roles and function of Global Project Team in new drug development